EOLS
Price
$6.03
Change
-$0.14 (-2.27%)
Updated
Jun 3, 04:59 PM (EDT)
Capitalization
406.98M
63 days until earnings call
Intraday BUY SELL Signals
INM
Price
$1.58
Change
+$0.06 (+3.95%)
Updated
Jun 3, 04:59 PM (EDT)
Capitalization
5.05M
Intraday BUY SELL Signals
Interact to see
Advertisement

EOLS vs INM

Header iconEOLS vs INM Comparison
Open Charts EOLS vs INMBanner chart's image
EOLS vs INM Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
EOLS vs. INM commentary
Jun 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EOLS is a Hold and INM is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 03, 2026
Stock price -- (EOLS: $6.18 vs. INM: $1.52)
Brand notoriety: EOLS and INM are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: EOLS: 62% vs. INM: 7%
Market capitalization -- EOLS: $406.98M vs. INM: $5.05M
EOLS [@Pharmaceuticals: Generic] is valued at $406.98M. INM’s [@Pharmaceuticals: Generic] market capitalization is $5.05M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EOLS’s FA Score shows that 0 FA rating(s) are green whileINM’s FA Score has 1 green FA rating(s).

  • EOLS’s FA Score: 0 green, 5 red.
  • INM’s FA Score: 1 green, 4 red.
According to our system of comparison, INM is a better buy in the long-term than EOLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EOLS’s TA Score shows that 3 TA indicator(s) are bullish while INM’s TA Score has 6 bullish TA indicator(s).

  • EOLS’s TA Score: 3 bullish, 5 bearish.
  • INM’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, INM is a better buy in the short-term than EOLS.

Price Growth

EOLS (@Pharmaceuticals: Generic) experienced а -1.12% price change this week, while INM (@Pharmaceuticals: Generic) price change was -11.34% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -2.57%. For the same industry, the average monthly price growth was +23.77%, and the average quarterly price growth was +16.17%.

Reported Earning Dates

EOLS is expected to report earnings on Aug 05, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-2.57% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EOLS($407M) has a higher market cap than INM($5.05M). INM YTD gains are higher at: 43.868 vs. EOLS (-7.068). INM has higher annual earnings (EBITDA): -7.07M vs. EOLS (-13.7M). EOLS has more cash in the bank: 49.8M vs. INM (6.96M). INM has less debt than EOLS: INM (532K) vs EOLS (165M). EOLS has higher revenues than INM: EOLS (302M) vs INM (4.51M).
EOLSINMEOLS / INM
Capitalization407M5.05M8,053%
EBITDA-13.7M-7.07M194%
Gain YTD-7.06843.868-16%
P/E RatioN/A0.01-
Revenue302M4.51M6,701%
Total Cash49.8M6.96M716%
Total Debt165M532K31,015%
FUNDAMENTALS RATINGS
EOLS vs INM: Fundamental Ratings
EOLS
INM
OUTLOOK RATING
1..100
8447
VALUATION
overvalued / fair valued / undervalued
1..100
71
Overvalued
26
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
4135
P/E GROWTH RATING
1..100
10079
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INM's Valuation (26) in the null industry is somewhat better than the same rating for EOLS (71) in the Pharmaceuticals Major industry. This means that INM’s stock grew somewhat faster than EOLS’s over the last 12 months.

INM's Profit vs Risk Rating (100) in the null industry is in the same range as EOLS (100) in the Pharmaceuticals Major industry. This means that INM’s stock grew similarly to EOLS’s over the last 12 months.

INM's SMR Rating (99) in the null industry is in the same range as EOLS (100) in the Pharmaceuticals Major industry. This means that INM’s stock grew similarly to EOLS’s over the last 12 months.

INM's Price Growth Rating (35) in the null industry is in the same range as EOLS (41) in the Pharmaceuticals Major industry. This means that INM’s stock grew similarly to EOLS’s over the last 12 months.

INM's P/E Growth Rating (79) in the null industry is in the same range as EOLS (100) in the Pharmaceuticals Major industry. This means that INM’s stock grew similarly to EOLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EOLSINM
RSI
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 22 days ago
76%
Bullish Trend 14 days ago
81%
Declines
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
65%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
EOLS
Daily Signal:
Gain/Loss:
INM
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JSVTX16.820.19
+1.14%
Janus Henderson Small-Mid Cap Value T
HDGCX35.18N/A
N/A
Hartford Dividend and Growth C
SEBLX31.23N/A
N/A
Touchstone Balanced A
FKKSX48.69N/A
N/A
Federated Hermes Kaufmann Small Cap R
MIEFX22.26N/A
N/A
Matthews Emerging Markets Equity Ins

EOLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, EOLS has been loosely correlated with LNTH. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if EOLS jumps, then LNTH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EOLS
1D Price
Change %
EOLS100%
-5.21%
LNTH - EOLS
36%
Loosely correlated
-0.85%
PRGO - EOLS
27%
Poorly correlated
-2.79%
ACET - EOLS
26%
Poorly correlated
-7.63%
INM - EOLS
26%
Poorly correlated
-2.24%
SNDL - EOLS
25%
Poorly correlated
-2.05%
More

INM and

Correlation & Price change

A.I.dvisor indicates that over the last year, INM has been loosely correlated with HYPD. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if INM jumps, then HYPD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INM
1D Price
Change %
INM100%
-2.24%
HYPD - INM
39%
Loosely correlated
-3.63%
OMER - INM
36%
Loosely correlated
-4.38%
PULM - INM
30%
Poorly correlated
-5.04%
IXHL - INM
28%
Poorly correlated
-6.15%
CRDF - INM
28%
Poorly correlated
+2.70%
More